Peter M.
- Country
- Germany
- Department
- Department of Dermatology
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
Data & Insights
Has run more than one trial at 191 of 389 partner sites.
Specializations
Advanced Melanoma Treatment
This investigator specializes in treating advanced and metastatic melanoma, with particular focus on unresectable cases and novel therapeutic combinations.
- First-line treatment strategies
- Combination immunotherapy approaches
- BRAF V600E/K mutation-positive melanoma
The research extends to evaluating various immunotherapy combinations and comparing their efficacy in treating advanced melanoma cases.
Early-Stage Melanoma Management
Expertise in adjuvant therapy for early-stage melanoma, focusing on high-risk Stage II and III melanoma patients following complete resection.
- Post-operative treatment protocols
- Recurrence prevention strategies
- Risk-stratified therapeutic approaches
The investigator evaluates treatment outcomes in resected melanoma cases with various risk profiles.
Cutaneous Squamous Cell Carcinoma
Research focus includes locally advanced cutaneous squamous cell carcinoma and development of post-surgical treatment strategies.
- High-risk disease management
- Adjuvant therapy protocols
- Multi-modal treatment approaches
The investigator studies innovative therapeutic interventions for high-risk cutaneous carcinoma cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.